Clinical Trial Detail

NCT ID NCT04340882
Title Phase 2 TaxRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (TaxRamPem)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

lung non-small cell carcinoma

Therapies

Docetaxel + Pembrolizumab + Ramucirumab

Age Groups: adult senior

No variant requirements are available.